Linqi Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9541934/publications.pdf

Version: 2024-02-01

96 papers	14,225 citations	81900 39 h-index	40979 93 g-index
113 all docs	113 docs citations	113 times ranked	24196 citing authors

#	Article	IF	Citations
1	Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 2020, 581, 215-220.	27.8	4,948
2	Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 2020, 584, 115-119.	27.8	1,524
3	The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell, 2020, 182, 1284-1294.e9.	28.9	1,362
4	Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 460.	7.4	1,061
5	Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Research, 2013, 23, 986-993.	12.0	588
6	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell, 2021, 184, 2362-2371.e9.	28.9	332
7	The changing face of HIV in China. Nature, 2008, 455, 609-611.	27.8	245
8	HIV-1 subtype and second-receptor use. Nature, 1996, 383, 768-768.	27.8	225
9	Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor. Journal of Biological Chemistry, 2008, 283, 11126-11134.	3.4	200
10	Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein. Science Translational Medicine, 2014, 6, 234ra59.	12.4	194
11	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity, 2021, 54, 1611-1621.e5.	14.3	190
12	Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. Journal of Medical Virology, 2006, 78, 1-8.	5.0	180
13	Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19079-19084.	7.1	132
14	Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein. Nature Communications, 2019, 10, 3068.	12.8	122
15	Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nature Communications, 2021, 12, 250.	12.8	108
16	A novel cell culture system modeling the SARS-CoV-2 life cycle. PLoS Pathogens, 2021, 17, e1009439.	4.7	102
17	Bring safe sex to China. Nature, 2012, 485, 576-577.	27.8	88
18	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host and Microbe, 2021, 29, 551-563.e5.	11.0	87

#	Article	IF	Citations
19	The humoral response and antibodies against SARS-CoV-2 infection. Nature Immunology, 2022, 23, 1008-1020.	14.5	84
20	Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nature Communications, 2021, 12, 4210.	12.8	82
21	HIV upsurge in China's students. Science, 2019, 364, 711-711.	12.6	79
22	Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution. Nature Communications, 2021, 12, 1607.	12.8	76
23	Antibodies and vaccines against Middle East respiratory syndrome coronavirus. Emerging Microbes and Infections, 2019, 8, 841-856.	6.5	71
24	Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. Scientific Reports, 2015, 5, 13133.	3.3	63
25	Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient. Journal of Infectious Diseases, 2018, 218, 1249-1260.	4.0	63
26	Delineating antibody recognition against Zika virus during natural infection. JCI Insight, 2017, 2, .	5.0	61
27	A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses. Journal of Virology, 2012, 86, 2978-2989.	3.4	60
28	Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein. Cell Reports, 2018, 24, 441-452.	6.4	57
29	Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2122954119.	7.1	57
30	Mucosal Priming with a Replicating-Vaccinia Virus-Based Vaccine Elicits Protective Immunity to Simian Immunodeficiency Virus Challenge in Rhesus Monkeys. Journal of Virology, 2013, 87, 5669-5677.	3.4	55
31	Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction. Cell Research, 2022, 32, 593-595.	12.0	55
32	Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. Cell Research, 2021, 31, 517-525.	12.0	54
33	Natural Mutations in the Receptor Binding Domain of Spike Glycoprotein Determine the Reactivity of Cross-Neutralization between Palm Civet Coronavirus and Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2007, 81, 4694-4700.	3.4	53
34	Genetic and Neutralization Sensitivity of Diverse HIV-1 env Clones from Chronically Infected Patients in China. Journal of Biological Chemistry, 2011, 286, 14531-14541.	3.4	51
35	A Dual-Reporter System for Real-Time Monitoring and High-throughput CRISPR/Cas9 Library Screening of the Hepatitis C Virus. Scientific Reports, 2015, 5, 8865.	3.3	51
36	In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to Sifuvirtide, a Novel HIV-1 Fusion Inhibitor. Journal of Biological Chemistry, 2011, 286, 3277-3287.	3.4	47

#	Article	IF	Citations
37	Potent neutralizing monoclonal antibodies against Ebola virus infection. Scientific Reports, 2016, 6, 25856.	3.3	46
38	Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice. Journal of Clinical Investigation, 2018, 128, 2239-2251.	8.2	44
39	Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody. PLoS Pathogens, 2016, 12, e1005454.	4.7	43
40	DeepHINT: understanding HIV-1 integration via deep learning with attention. Bioinformatics, 2019, 35, 1660-1667.	4.1	41
41	Genetic Characterization of Diverse HIV-1 Strains in an Immigrant Population Living in New York City. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 399-404.	2.1	40
42	Forecasting influenza activity using self-adaptive AI model and multi-source data in Chongqing, China. EBioMedicine, 2019, 47, 284-292.	6.1	36
43	Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection. Emerging Microbes and Infections, 2019, 8, 760-772.	6.5	36
44	Comprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infection. Nature Communications, 2015, 6, 8855.	12.8	35
45	Migration Patterns of Hepatitis C Virus in China Characterized for Five Major Subtypes Based on Samples from 411 Volunteer Blood Donors from 17 Provinces and Municipalities. Journal of Virology, 2014, 88, 7120-7129.	3.4	32
46	A Single Injection of Human Neutralizing Antibody Protects against Zika Virus Infection and Microcephaly in Developing Mouse Embryos. Cell Reports, 2018, 23, 1424-1434.	6.4	29
47	Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays. Emerging Microbes and Infections, 2020, 9, 2269-2277.	6.5	29
48	The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. Journal of Virological Methods, 2007, 144, 17-26.	2.1	28
49	A Single Residue within the V5 Region of HIV-1 Envelope Facilitates Viral Escape from the Broadly Neutralizing Monoclonal Antibody VRC01. Journal of Biological Chemistry, 2012, 287, 43170-43179.	3.4	28
50	MSM and HIV-1 infection in China. National Science Review, 2015, 2, 388-391.	9.5	28
51	Intranasal Immunization with Recombinant HA and Mast Cell Activator C48/80 Elicits Protective Immunity against 2009 Pandemic H1N1 Influenza in Mice. PLoS ONE, 2011, 6, e19863.	2.5	25
52	Structural Basis for Neutralization and Protection by a Zika Virus-Specific Human Antibody. Cell Reports, 2019, 26, 3360-3368.e5.	6.4	24
53	Broadly neutralizing antibodies and vaccine design against HIV-1 infection. Frontiers of Medicine, 2020, 14, 30-42.	3.4	24
54	Loss of Spike N370 glycosylation as an important evolutionary event for the enhanced infectivity of SARS-CoV-2. Cell Research, 2022, 32, 315-318.	12.0	24

#	Article	IF	Citations
55	Unraveling of a Neutralization Mechanism by Two Human Antibodies against Conserved Epitopes in the Globular Head of H5 Hemagglutinin. Journal of Virology, 2013, 87, 3571-3577.	3.4	23
56	A safety consideration of mesenchymal stem cell therapy on COVID-19. Stem Cell Research, 2020, 49, 102066.	0.7	22
57	Differential impact of non-pharmaceutical public health interventions on COVID-19 epidemics in the United States. BMC Public Health, 2021, 21, 965.	2.9	21
58	Comprehensive Analysis of Pathogen-specific Antibody Response in Vivo Based on an Antigen Library Displayed on Surface of Yeast. Journal of Biological Chemistry, 2011, 286, 33511-33519.	3.4	20
59	Discovery of Imidazo[1,2-Î±][1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor. ACS Medicinal Chemistry Letters, 2015, 6, 977-981.	2.8	19
60	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. IScience, 2022, 25, 104043.	4.1	19
61	Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies. PLoS Pathogens, 2019, 15, e1007819.	4.7	18
62	Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 697074.	4.8	18
63	A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus. Nature Communications, 2021, 12, 6624.	12.8	18
64	Discovery of Novel Small Molecule Anti-HCV Agents via the CypA Inhibitory Mechanism Using O-Acylation-Directed Lead Optimization. Molecules, 2015, 20, 10342-10359.	3.8	16
65	Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay. ACS Infectious Diseases, 2019, 5, 778-787.	3.8	15
66	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. Frontiers in Immunology, 2021, 12, 766821.	4.8	15
67	Development of a Potent and Protective Germline-Like Antibody Lineage Against Zika Virus in a Convalescent Human. Frontiers in Immunology, 2019, 10, 2424.	4.8	14
68	A vaccine crisis in the era of social media. National Science Review, 2018, 5, 8-10.	9.5	13
69	Digitalized Adaptation of Oncology Trials during and after COVID-19. Cancer Cell, 2020, 38, 148-149.	16.8	13
70	Anonymous Linkage Between College Students and Human Immunodeficiency Virus (HIV) Facilities: Systematic Evaluation of Urine Self-Collection for HIV Testing Initiative in China. Clinical Infectious Diseases, 2021, 73, e1108-e1115.	5.8	12
71	Stabilized diverse HIV-1 envelope trimers for vaccine design. Emerging Microbes and Infections, 2020, 9, 775-786.	6.5	12
72	Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5682-5686.	2.2	11

#	Article	IF	Citations
73	Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses. Journal of Biological Chemistry, 2018, 293, 830-846.	3.4	11
74	Complementary recognition of the receptor-binding site of highly pathogenic H5N1 influenza viruses by two human neutralizing antibodies. Journal of Biological Chemistry, 2018, 293, 16503-16517.	3.4	11
75	A pathogen-like antigen based vaccine confers immune protection against SARS-CoV-2 in non-human primates. Cell Reports Medicine, 2021, 2, 100448.	6.5	11
76	Open letter from Chinese HIV professionals on human genome editing. Lancet, The, 2019, 393, 26-27.	13.7	10
77	Role of efficient testing and contact tracing in mitigating the COVID-19 pandemic: a network modelling study. BMJ Open, 2021, 11, e045886.	1.9	10
78	Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection. Cell Discovery, 2021, 7, 123.	6.7	10
79	SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. Frontiers in Immunology, 0, 13, .	4.8	10
80	A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during InÂVivo Adaptation. Cell Reports, 2019, 27, 2593-2607.e5.	6.4	8
81	Spatiotemporal hierarchy in antibody recognition against transmitted HIV-1 envelope glycoprotein during natural infection. Retrovirology, 2016, 13, 12.	2.0	7
82	Structural basis of severe acute respiratory syndrome coronavirus 2 infection. Current Opinion in HIV and AIDS, 2021, 16, 74-81.	3.8	7
83	Both structure and function of human monoclonal antibodies contribute to enhancement of Zika virus infectivity in vitro. Science China Life Sciences, 2017, 60, 1396-1398.	4.9	6
84	An integrated framework for modelling quantitative effects of entry restrictions and travel quarantine on importation risk of COVID-19. Journal of Biomedical Informatics, 2021, 118, 103800.	4.3	6
85	Structural and functional definition of a vulnerable site on the hemagglutinin of highly pathogenic avian influenza A virus H5N1. Journal of Biological Chemistry, 2019, 294, 4290-4303.	3.4	5
86	Two immunogenic recombinant protein vaccine candidates showed disparate protective efficacy against Zika virus infection in rhesus macaques. Vaccine, 2021, 39, 915-925.	3.8	5
87	Tandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression. Cell Reports, 2021, 36, 109611.	6.4	5
88	Combinatorial library-based profiling of the antibody response against hepatitis C virus in humans. Journal of General Virology, 2015, 96, 52-63.	2.9	4
89	Persistence of VRC01-resistant HIV-1 during antiretroviral therapy. Science China Life Sciences, 2014, 57, 88-96.	4.9	3
90	Surging publications on the COVID-19 pandemic. Clinical Microbiology and Infection, 2021, 27, 484-486.	6.0	3

#	Article	IF	Citations
91	Broadly neutralizing antibodies against SARS-CoV-2 variants. , 2022, 1, 20220005.		3
92	HLA-mismatched allogeneic adoptive immune therapy in severely immunosuppressed AIDS patients. Signal Transduction and Targeted Therapy, 2021, 6, 174.	17.1	2
93	No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5115-E5115.	7.1	1
94	Single N277A substitution in C2 of simian immunodeficiency virus envelope influences vaccine-elicited CD4i neutralizing and anti-V2 antibody responses. Vaccine, 2017, 35, 2582-2591.	3.8	1
95	V4 region of the HIV-1 envelope gene mediates immune escape and may not promote the development of broadly neutralizing antibodies. Vaccine, 2018, 36, 7700-7707.	3.8	1
96	A commentary of â€œâ€˜Shock and Killâ€™ of Latent HIVâ€•in 10 remarkable discoveries from 2020 in Nature. Fundamental Research, 2022, , .	3.3	0